Drugs / Noradrenaline

Trials 12

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 35 trials · 3 missed
Phase 3 NCT05014581 Aug 2024 → Mar 2026 overdue respiratory failure University of Turin, Italy Recruiting No outcome recorded
Phase 3 NCT05931601 Dec 2023 → Dec 2026 expected dehydration polycythemia, hypotensive disorder Odense University Hospital Recruiting No outcome recorded
Phase 3 NCT05335954 Apr 2022 → Dec 2023 heart disorder, hypotensive disorder Nantes University Hospital Completed Missed primary
Phase 3 NCT04569942 Oct 2021 → Feb 2026 overdue — Australian and New Zealand Intensive Care Research Centre Active not recruiting Missed primary
Phase 3 NCT03822091 Jan 2019 → Jan 2020 hepatorenal syndrome Post Graduate Institute of Medical Education and Research, Chandigarh Completed Missed primary
Phase 41 trial
Phase 4 NCT05168462 Oct 2022 → Apr 2027 expected cardiogenic shock, myocardial infarction Academic Medical Center - University of Amsterdam Recruiting No outcome recorded
Phase not applicable6 trials
— NCT07795710 Jan 2024 — Minia University Completed No outcome recorded
— NCT07067944 Jul 2023 → Mar 2024 — Tanta University Completed No outcome recorded
— NCT04376281 Dec 2019 → Aug 2021 — Cairo University Completed No outcome recorded
— NCT02573727 Oct 2015 → Jan 2017 liver failure Institute of Liver and Biliary Sciences, India Completed No outcome recorded
— NCT01649037 Aug 2012 → Jun 2015 hepatorenal syndrome Institute of Liver and Biliary Sciences, India Withdrawn No outcome recorded Stop: Business
— NCT00901745 May 2009 → Apr 2010 heart disorder, isoproterenol-mediated vasodilatation University of Edinburgh Completed No outcome recorded
Comparator or background therapy19 trials
Phase 2 NCT05670028 Background Jun 2023 → Jan 2026 ischemic stroke, vascular insufficiency disorder Beijing Tiantan Hospital Unknown No outcome recorded
Phase 2 NCT04586790 Background Oct 2020 → Jan 2021 — Ahmed talaat ahmed aly Unknown No outcome recorded
Phase 3 NCT06885268 Comparator Jun 2025 → Jun 2027 expected — Jagiellonian University Recruiting No outcome recorded
Phase 3 NCT05207280 Background Oct 2022 → Nov 2024 infectious disease with sepsis Andalusian Public Foundation for Health Research in Seville Unknown No outcome recorded
Phase 3 NCT05481723 Comparator Jul 2022 → Jul 2027 expected — Centre Hospitalier Universitaire, Amiens Recruiting No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2018-03-01 Sumitomo Pharma America, Inc. Pfizer and Sumitomo Dainippon Pharma Commence the Co-Promotion of Serotonin-Norepinephrine Reuptake Inhibitor EFFEXOR SR Capsules sumitomo-pharma.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 31 sources stand behind the page.

FieldValueCited text
Known as Noradrenaline “To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or...” NCT05670028 ↗
32

“The Effect of Oral Midodrine Versus Oral Desmopressin Acetate Use for Liberation From IV Noradrenaline in Intensive Care Unit Patients Recovering From Spinal Shock .” NCT04586790 ↗

“To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure” NCT02573727 ↗

“In the case Terlipressin is not tolerated treatment with Noradrenaline may be considered following actual guidelines.” NCT05346393 ↗

“commence a vasopressor infusion (e.g. noradrenaline) and titrate according to local practice” NCT04569942 ↗

“pressor support (noradrenaline, doubutamine, dopamine) as needed” NCT04243655 ↗

“Group 2( N) will receive bolus dose of noradrenaline 4 ug” NCT07795710 ↗

“noradrenaline max. 0.15 µg/kg/min” NCT03118024 ↗

“noradrenaline” NCT05341167 ↗

NCT05014581 ↗

NCT05733403 ↗

Show 22 more sources

Known as norepinephrine “Noradrenaline (or norepinephrine) "is a potent peripheral vasoconstrictor which acts both on arterial and venous substrates (alpha-adrenergic effect) and as a cardiac inotropic...” NCT06265259 ↗
Action Activate “Noradrenaline acts as an agonist at α-adrenergic receptors with mild β-agonistic activity.” NCT03822091 ↗
Route Other “Infusion of up to 480 picomol/ml of noradrenaline will be infused.” NCT00901745 ↗